The 2020 KDIGO guidelines clearly recommend the long-term use of renin-angiotensin system inhibitors (RASI) for IgAN patients with urinary protein regardless of whether they have hypertension or not, and RASI drugs provide supportive care. The gene discussed is REN; the disease is hypertensive disorder.